WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |

Search International and National Patent Collections
World Intellectual Property Organization
Machine translation
1. (WO2011135869) NOVEL MUC1 ANTIBODY
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2011/135869    International Application No.:    PCT/JP2011/002520
Publication Date: 03.11.2011 International Filing Date: 28.04.2011
C12N 15/09 (2006.01), A61K 39/395 (2006.01), A61P 35/00 (2006.01), C07K 16/18 (2006.01), G01N 33/53 (2006.01), G01N 33/574 (2006.01), C12P 21/08 (2006.01)
Applicants: Shionogi & Co., Ltd. [JP/JP]; 1-8, Doshomachi 3-chome, Chuo-ku, Osaka-shi, Osaka 5410045 (JP) (For All Designated States Except US).
NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY [JP/JP]; Kita 8-jyo Nishi 5-chome, Kita-ku, Sapporo-shi, Hokkaido 0600808 (JP) (For All Designated States Except US).
NISHIMURA, Shin-Ichiro; (For US Only).
NAITO, Shoichi [JP/JP]; (JP) (For US Only).
OHYABU, Naoki [JP/JP]; (JP) (For US Only).
TAKAHASHI, Tatsuya [JP/JP]; (JP) (For US Only).
NUMATA, Yoshito [JP/JP]; (JP) (For US Only).
KAWAMOTO, Keiko [JP/JP]; (JP) (For US Only)
Inventors: NISHIMURA, Shin-Ichiro; .
NAITO, Shoichi; (JP).
OHYABU, Naoki; (JP).
TAKAHASHI, Tatsuya; (JP).
NUMATA, Yoshito; (JP).
Agent: YAMAMOTO, Shusaku; Fifteenth Floor, Crystal Tower, 2-27, Shiromi 1-chome, Chuo-ku, Osaka-shi, Osaka 5406015 (JP)
Priority Data:
2010-104033 28.04.2010 JP
(JA) 新規なMUC1抗体
Abstract: front page image
(EN)Disclosed is an MUC1 antibody having high specificity for cancer cells. Specifically, the present inventors have discovered that a sugar chain in MUC1 specific to cancer cells can be recognized specifically, and by extension, cancer cells expressing MUC1 having a sugar chain specific to cancer cells can be recognized. For example, an antibody, in which the specificity of MUC1 for cancer-related structures is 40 times or more that of MUC1 for normal-tissue-related structures, and an antigen-binding fragment thereof or MUC1-binding molecule thereof are provided.
(FR)La présente invention concerne un anticorps MUC1 de spécificité élevée vis-à-vis des cellules cancéreuses. Les présents inventeurs ont spécifiquement découvert qu'une chaîne sucrée de MUC1 spécifique des cellules cancéreuses peut être reconnue spécifiquement, et par extension, que les cellules cancéreuses exprimant MUC1 portant une chaîne sucrée spécifique de cellules cancéreuses peuvent être reconnues. Par exemple, la présente invention concerne un anticorps dont la spécificité vis-à-vis de MUC1 dans les structures de type cancéreux est au moins 40 fois celle vis-à-vis de MUC1 dans les structures de tissus normaux, ainsi que l'un de ses fragments se liant à l'antigène ou l'une de ses molécules se liant à MUC1.
(JA)本発明は、がん細胞に特異性の高いMUC1抗体を提供することを課題とする。 上記課題は、本発明者らが、MUC1においてがん特異的な糖鎖を特異的に認識し、ひいてはそのようながん細胞特異的な糖鎖を有するMUC1を発現するがん細胞を認識できることを見出したことによって、解決した。本発明は例えば、MUC1のがん関連構造に対する特異性が、MUC1の正常組織関連構造に対するものに比べ40倍以上である、抗体、その抗原結合性断片またはMUC1結合分子を提供する。
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: Japanese (JA)
Filing Language: Japanese (JA)